Healthcare Industry News:  cell therapy 

Regenerative Medicine Personnel

 News Release - April 1, 2008

Stem Cell Therapy International Appoints Dr. David L. Stark as President in Anticipation of the Upcoming Merger With Histostem, Ltd. of Korea

TAMPA, FL and SEOUL, SOUTH KOREA--(Healthcare Sales & Marketing Network)--Apr 1, 2008 -- Stem cell therapy International, Inc. (OTC BB:SCII.OB ) and Histostem Corp. (Korea Histostem) announced today it has appointed Dr. David L. Stark as president in anticipation of the upcoming merger with Histostem of Korea, one of the world's leading umbilical cord stem cell blood banks and research companies in the field of stem cell treatments for various illnesses. After the closing of the merger between SCII and Histostem the name of the combined entities will be changed to AmStem International Corporation and Dr. Stark will continue in his capacity as president and member of the board of directors. Dr. Hoon Han of Histostem will be chairman of the board and CEO of AmStem International.

"Dr. Stark is an internationally recognized research innovator," explains Calvin Cao, Chairman and CEO of SCII. Formerly the Director of the National Institute of Clinical Research (NICR), Dr. Stark has been responsible for the design, organization and implementation of clinical trials for pharmaceutical and device companies -- from multi-billion dollar corporations to small, entrepreneurial start-ups. He has a broad background in designing, conducting, and monitoring clinical trials of new pharmaceuticals and devices and he will be able to use that experience in assisting AmStem to pursue the filing of various stem cell treatment applications with the U.S. FDA as well as assist in the worldwide marketing of these stem treatments to physicians, hospitals and clinics in the numerous countries interested in these treatment modalities.

Dr. Stark's involvement as president will seek to establish AmStem International as a worldwide leader in meeting the growing need for transplant grade umbilical cord blood stem cells -- which have been identified as a potential treatment for more than 80 diseases ranging from leukemia to sickle cell anemia. With over 80,000 umbilical cord blood units already on hand in the current inventory of Histostem, Ltd., Dr. Stark will work to assist Dr. Hoon Han, CEO of AmStem International, to oversee the ongoing collection and preparation of donated umbilical cord blood in order to maintain a valuable inventory of HLA (human leukocyte antigen) typed and tested stem cells; all indexed in a dynamic new database platform to speed the matching process. This current inventory of 80,000 umbilical cord blood units in the "public bank" represents a potentially very valuable asset of AmStem International since a single unit of public bank umbilical cord blood has been known to be sold on world markets for as much as $25,000. "Although this makes units held in cord blood banks among the world's most valuable commodities, we should not speculate about future value which could be higher or lower than previous reported prices depending upon various circumstances such as the length of time it takes the FDA to approve stem cell procedures for use in the Unites States," cautioned Dr. Stark, who went on to observe, "We can afford to be patient since all of the 80,000 units are in a cryobank so they are protected and can be used many years from now, if necessary."

Dr. Hoon Han, CEO and chairman of Histostem Ltd., expressed the strategic value of having Dr. Stark as President of AmStem International Corp. "David brings not just a knowledge of stem cells, but the ability to leverage his knowledge of the FDA regulatory requirements to rapidly develop and market this innovative approach to umbilical cord blood stem cell banking, allowing us almost instantly to be a major competitor in the international stem cell market."

About AmStem International Corp.

AmStem International Corp., as the merged businesses of Stem cell therapy International and Histostem, Ltd. will be known, intends to take its place as a world leader in the research community with the introduction of a new platform for developing contaminant-free human stem cells that will serve as a catalyst for bringing new medical therapies to market.

About Histostem, Ltd.

Histostem, Ltd. started in Seoul, Korea in 2000. To date it has treated more than 500 patients with stem cells and currently has 56 full time employees and 28 part-time employees. Histostem's intellectual property portfolio consists of five patents that have been granted, and 6 patents pending. A comprehensive list of Histostem's achievements can be found at the company website (click on English version when entering the site).

Forward-Looking Statements. This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct.

Source: Stem Cell Therapy International

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.